Patents Represented by Attorney Edward L. Mandell
  • Patent number: 5344656
    Abstract: Rate controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent or a plasticizer for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation, and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and preferably at least 75% initial equilibrated agent loading is in the reservoir layer.
    Type: Grant
    Filed: June 16, 1993
    Date of Patent: September 6, 1994
    Assignee: ALZA Corporation
    Inventors: David J. Enscore, Patricia S. Campbell, James L. Osborne, Melinda K. Smart, Su I. Yum
  • Patent number: 5344394
    Abstract: A two phase adhesive matrix for use in an electrically powered iontophoretic delivery device is provided. The adhesive matrix comprises an adhesive hydrophobic polymer phase and about 15 to 60 wt. % on a dry weight basis of a hydrophilic polymer phase distributed through the hydrophobic polymer phase. The hydrophilic phase forms upon hydration an interconnecting network of aqueous pathways for passage of the agent through the adhesive. The adhesive can be used to adhere an electrode assembly of an iontophoretic delivery device to a body surface such as skin or a mucosal membrane. Alternatively, the adhesive can be used to adhere together two or more elements of an iontophoretic delivery device.
    Type: Grant
    Filed: May 27, 1993
    Date of Patent: September 6, 1994
    Assignee: ALZA Corporation
    Inventors: J. Richard Gyory, Ronald P. Haak, Felix Theeuwes, Patrick J. Lew
  • Patent number: 5342623
    Abstract: Rate controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent or a plasticizer for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation, and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and preferably at least 75% initial equilibrated agent loading is in the reservoir layer.
    Type: Grant
    Filed: June 18, 1993
    Date of Patent: August 30, 1994
    Assignee: Alza Corporation
    Inventors: David J. Enscore, Patricia S. Campbell, James L. Osborne, Melinda K. Smart, Su I. Yum
  • Patent number: 5330762
    Abstract: A dosage form is provided for administering a drug of the formula ##STR1## to a patient to produce an anxiolytic benefit in the patient.
    Type: Grant
    Filed: January 27, 1993
    Date of Patent: July 19, 1994
    Assignee: Alza Corporation
    Inventors: Atul D. Ayer, Dana Ridzon
  • Patent number: 5326341
    Abstract: An iontophoretic agent delivery device having donor and counter electrodes comprised of either metal or a hydrophobic polymer loaded with a conductive filler is provided. The agent reservoir in the donor electrode assembly contains about 10 to 60 wt. % hydrophobic polymer, about 10 to 60 wt. % hydrophilic polymer, and up to 50% agent. Similarly, the electrolyte reservoir contains about 10 to 60 wt. % hydrophobic polymer, about 10 to 60 wt. % hydrophilic polymer, and up to 50% electrolyte. The agent reservoir, the electrolyte reservoir and the electrodes are preferably in the form of films which are laminated to one another. The hydrophobic polymer component in the agent/electrolyte reservoir prevents the reservoir from delaminating from the metal/hydrophobic polymer based electrode, even after hydration of the reservoirs.
    Type: Grant
    Filed: September 3, 1992
    Date of Patent: July 5, 1994
    Assignee: Alza Corporation
    Inventors: Patrick J. Lew, J. Richard Gyory
  • Patent number: 5326571
    Abstract: A dosage form is disclosed comprising a wall surrounding a compartment, which comprises a first composition comprising a carboxymethylcellulose and a second composition comprising a higher molecular weight carboxymethylcellulose. The first composition comprises a dosage amount of drug that delivers from the dosage form at a controlled rate over time.
    Type: Grant
    Filed: September 4, 1992
    Date of Patent: July 5, 1994
    Assignee: ALZA Corporation
    Inventors: Jeri D. Wright, Brian L. Barclay, David R. Swanson
  • Patent number: 5322502
    Abstract: A membrane capable of inhibiting agent release from a delivery system when no electrical current is flowing and yet provide minimal impedance to electrically-assisted agent delivery, useful both for incorporating into electrotransport agent delivery systems and for use in measuring agent release rates in in vitro testing.
    Type: Grant
    Filed: January 13, 1993
    Date of Patent: June 21, 1994
    Assignee: Alza Corporation
    Inventors: Felix Theeuwes, J. Richard Gyory, Ronald P. Haak
  • Patent number: 5320598
    Abstract: A dry-state iontophoretic drug delivery device (10, 70, 80) is provided. The device has drug and electrolyte reservoirs (15, 16) which are initially in a non-hydrated condition. A liquid-containing pouch (21, 22) is provided. In certain embodiments the liquid is contained in breakable capsules within the pouch. Water or other liquid can be released from the capsules in the pouch by squeezing or flexing the pouches (21,22). Alternatively, the liquid can be released from the pouches (21,22) using pouch piercing pins (36,37). The liquid released from the pouches (21,22) hydrates the drug and electrolyte reservoirs (15, 16) and activates the device. In another embodiment, the device (20, 20a) has liquid-containing gel layers (31,32) which are initially separated from their respective electrode assemblies (8, 9). Liquid-wicking pathways (27,28) are provided to carry the liquid from the gel layers (31,32) to the drug and electrolyte layers (15, 16).
    Type: Grant
    Filed: May 12, 1992
    Date of Patent: June 14, 1994
    Assignee: ALZA Corporation
    Inventors: Ronald P. Haak, J. Richard Gyory, Felix Theeuwes, Felix A. Landrau, Nathan Roth, Robert M. Myers
  • Patent number: 5312389
    Abstract: An osmotically driven syringe (20, 60) is disclosed which can be used to deliver a beneficial agent such as a drug, at varying pre-determined rates over multiple periods of time. The syringe (20, 60) is driven by an osmotic engine (10) having a shaped wall (12) containing an osmotic agent (17) and/or a gas generating means (19), such as an effervescent couple. The wall (12) is composed of a semipermeable and/or microporous material which is permeable to an external liquid (e.g., water) but which is substantially impermeable to the osmotic agent (17) and the gas generated by the gas generating means (19). The wall (12) has a passageway (13) therethrough to provide a flow path for the driving fluid generated by the engine (10). The osmotic agent(s) (17) and/or the gas generating means (19) are placed in the engine (10) in such a way as to drive engine (10) at different pumping rates (R.sub.1, R.sub.2) over sequential periods of time (t.sub.0 to t.sub.1 and t.sub.1 to t.sub.2).
    Type: Grant
    Filed: April 3, 1992
    Date of Patent: May 17, 1994
    Inventors: Felix Theeuwes, Su Il Yum
  • Patent number: 5310561
    Abstract: A dosage form is disclosed comprising an antiemetic and antinausea drug for treating vomiting and nausea.
    Type: Grant
    Filed: September 21, 1992
    Date of Patent: May 10, 1994
    Assignee: Alza Corporation
    Inventors: Francisco Jao, Hoa T. Huynh, Patrick S. L. Wong
  • Patent number: 5294770
    Abstract: Tablet treating system 10 treats a series of pharmaceutical tablets 50T with pulses of laser energy 24P within at least one predetermined treatment site 50S on each tablet. A tablet conveyer 12 continuously moves individual tablets along a tablet path 10P. A Laser 14 provides the pulses of laser energy along a stationary laser path which crosses the tablet path defining a stationary intersection zone 14Z common to both paths. The tablet path has periodic treatment windows 20W during which the treatment sites 50S on the moving tablets pass through the stationary intersection zone. The operation of the laser has periodic laser ready windows 24W during which the laser may be fired. A controller 16 is responsive to the movement of the tablet conveyer and to the operation of the laser for activating the laser and treating the tablets. The controller activates the laser when a tablet is passing through the intersection zone and the tablet treatment window coincides with the laser ready window.
    Type: Grant
    Filed: January 14, 1992
    Date of Patent: March 15, 1994
    Assignee: Alza Corporation
    Inventors: Thomas A. Riddle, Johan H. Geerke, Keith P. Minton
  • Patent number: 5288289
    Abstract: A dry-state iontophoretic drug delivery device (10, 70, 80) is provided. The device has drug and electrolyte reservoirs (15, 16) which are initially in a non-hydrated condition. A liquid-containing pouch (21, 22) is provided. In certain embodiments the liquid is contained in breakable capsules within the pouch. Water or other liquid can be released from the capsules in the pouch by squeezing or flexing the pouches (21,22). Alternatively, the liquid can be released from the pouches (21,22) using pouch piercing pins (36,37). The liquid released from the pouches (21,22) hydrates the drug and electrolyte reservoirs (15, 16) and activates the device. In another embodiment, the device (20, 20a) has liquid-containing gel layers (31,32) which are initially separated from their respective electrode assemblies (8, 9). Liquid-wicking pathways (27,28) are provided to carry the liquid from the gel layers (31,32) to the drug and electrolyte layers (15, 16).
    Type: Grant
    Filed: May 12, 1992
    Date of Patent: February 22, 1994
    Assignee: ALZA Corporation
    Inventors: Ronald P. Haak, J. Richard Gyory, Felix Theeuwes, Felix A. Landrau, Nathan Roth, Robert M. Myers
  • Patent number: 5286491
    Abstract: A method of preventing sensitization in transdermal drug delivery by the inclusion of a corticosteroid, which will be coextensively coadministered with the sensitizing agent.
    Type: Grant
    Filed: May 18, 1992
    Date of Patent: February 15, 1994
    Assignee: Alza Corporation
    Inventors: Alfred Amkraut, Jane E. Shaw
  • Patent number: 5250028
    Abstract: A drug formulation chamber for an intravenous administration set is provided. The intravenous administration set includes a container of an IV fluid, a drip chamber, a drug formulation chamber, and an adapter-needle assembly. The drug formulation chamber has a fluid inlet and a fluid outlet for maintaining a flow of IV fluid through the chamber. A portion of the chamber wall is comprised of a material which is permeable to the drug but which prevents convective loss of the IV fluid. A transdermal-type drug delivery device is adhered to the semipermeable/microporous wall portion. Drug is delivered by the delivery device through the wall portion using permeation enhancers and into the flowing IV fluid. The device delivers drug into the IV fluid at a rate that is independent of the flow rate of IV fluid through the formulation chamber. The rate of drug delivery from the device into the IV fluid is controlled by either the wall portion or a membrane layer in the drug delivery device.
    Type: Grant
    Filed: August 9, 1991
    Date of Patent: October 5, 1993
    Assignee: ALZA Corporation
    Inventors: Felix Theeuwes, Su I. Yum
  • Patent number: 5248310
    Abstract: An osmotic device (10) for delivering a beneficial drug, such as an anti-fungal, into the mouth of a human patient is disclosed. The device (10) has a size and shape adapting it to be comfortably retained in the mouth for extended periods of time. The device (10) comprises a wall (12) surrounding a compartment (13) housing a layer of an agent (14) that is insoluble to very soluble in aqueous biological fluids, e.g., saliva, and a layer (16) of a fluid swellable, hydrophilic polymer. A passageway (17) in the wall (12) connects the agent (14) with the exterior of the device (10). The wall (12) is permeable to the passage of aqueous biological fluid but substantially impermeable to the passage of the hydrophilic polymer (16). In one embodiment the beneficial agent (14) has a different color than the hydrophilic polymer (16). The wall (12) is sufficiently translucent to permit the patient to see the amount of drug/beneficial agent (14) remaining to be delivered.
    Type: Grant
    Filed: March 27, 1992
    Date of Patent: September 28, 1993
    Assignee: Alza Corporation
    Inventors: Brian L. Barclay, Jerry D. Childers, Jeri D. Wright, Virgil A. Place, Patrick S.-L. Wong
  • Patent number: 5246711
    Abstract: A dosage form is provided for administering a drug of the formula ##STR1## to a patient to produce an anxiolytic benefit in the patient.
    Type: Grant
    Filed: September 10, 1992
    Date of Patent: September 21, 1993
    Assignee: ALZA Corporation
    Inventors: Atul D. Ayer, Dana Ridzon
  • Patent number: 5246709
    Abstract: A dosage form is disclosed comprising an antiemetic and antinausea drug for treating vomiting and nausea.
    Type: Grant
    Filed: September 21, 1992
    Date of Patent: September 21, 1993
    Assignee: Alza Corporation
    Inventors: Francisco Jao, Hoa T. Huynh, Patrick S. L. Wong
  • Patent number: 5246417
    Abstract: Apparatus (11) for delivery of a medicament, drug or other therapeutic agent transdermally to a body by iontophoresis is provided. The apparatus (11) provides a means (13) for measuring and displaying the cumulative amount of the medicament delivered to the body by monitoring the amount of a metal, initially present at the anode (45), that is transferred to the cathode (41) in a subsidiary electrolyte cell (47) through which the drive current for the apparatus (11) passes. Optionally, the apparatus also provides a plurality of light emitting devices (63-1) that display a measure of the cumulative amount of medicament delivered, by use of visually distinguishable light colors or by use of binary encoding in the light display.
    Type: Grant
    Filed: December 11, 1991
    Date of Patent: September 21, 1993
    Assignee: ALZA Corporation
    Inventors: Ronald P. Haak, Felix Theeuwes, David K. Roe
  • Patent number: 5246710
    Abstract: A dosage form is provided for administering a drug of the formula ##STR1## to a patient to produce an anxiolytic benefit in the patient.
    Type: Grant
    Filed: September 10, 1992
    Date of Patent: September 21, 1993
    Assignee: ALZA Corporation
    Inventors: Atul D. Ayer, Dana Ridzon
  • Patent number: D349960
    Type: Grant
    Filed: December 31, 1992
    Date of Patent: August 23, 1994
    Assignee: Alza Corporation
    Inventors: J. Richard Gyory, Jay Wilson